Adapted CAR-T Therapy Shows Promise in Myasthenia Gravis
The first study to use an RNA-based chimeric antigen receptor T-cell (rCAR-T)…
Browsing Tag
Gravis
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for…
First-and-only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis…
FDA Greenlights New Myasthenia Gravis Drug
The FDA approved rozanolixizumab-noli (Rystiggo), a neonatal Fc receptor…
Muscular Dystrophy Association Celebrates FDA Approval of UCB’s RYSTIGGO for the…
New York, June 27, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of RYSTIGGO (rozanolixizumab-noli) for…
Muscular Dystrophy Association Celebrates FDA Approval of argenx’s Vyvgart Hytrulo…
New York, June 20, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of subcutaneous (SC) Vyvgart Hytrulo…
Myasthenia Gravis Treatment Market to Reach $3.1 Billion, Globally, by 2032 at 6.5%…
<!-- Name:DistributionId Value:8839512 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Myasthenia Gravis Tied to Elevated Risk for Severe COVID
People with myasthenia gravis were at higher risk for severe cases of COVID-19, including…
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients…
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global…
Global Myasthenia Gravis (MG) Disease Market Garnered About USD 1.5 Billion in 2021;…
New York, July 01, 2022 (GLOBE NEWSWIRE) -- According to one of the statistics published by the National Center for Biotechnology Information (NCBI), the prevalence rate for Myasthenia…
Myasthenia Gravis Treatment Market Size [2022-2029]: $2.03 Billion by 2028 at CAGR of…
Pune, India, May 26, 2022 (GLOBE NEWSWIRE) -- The global myasthenia gravis treatment market size is anticipated to reach USD 2.03 billion by 2028 and exhibit a CAGR of 7.5% during the…